AI Financial Announces Drew Therapeutics Rebrand for Biotech Segment
AI Financial Corporation said its biotech segment, previously known as Alyea Therapeutics Corporation, will be rebranded as Drew Therapeutics Corporation in memory of Andrew Witkoff.
AI Financial Corporation (Nasdaq:AIFC)(FRA:5AR1) has announced that its biotech segment will be rebranded as Drew Therapeutics Corporation, a name chosen to honour Andrew Witkoff, the brother of Chairman Zach Witkoff. Andrew Witkoff died from an opioid overdose in 2011 at the age of 22.
The business currently operates under the Alyea Therapeutics Corporation name. AI Financial said the biotech segment is intended to become a separate, independent public company, as previously announced.
AI Financial said the new identity reflects the biotech business’s work on treatments for pain that do not rely on opioids. Its stated tagline is “From Pain Comes Purpose,” which the company associated with opioid-awareness efforts, support for families affected by addiction and research into alternative pain treatments.
Chief Executive Officer Tony Isaac said Andrew Witkoff’s story supports the company’s focus on developing non-addictive painkillers. Chairman Zach Witkoff said he hoped Andrew’s name would continue to inspire work on alternatives to addictive drugs.
AI Financial said more than 700,000 Americans had died from opioids over the past 10 years. The company also cited figures stating that Americans represent 5 percent of the world’s population while consuming 80% of the world’s oxycodone.
Drew Therapeutics is focused on non-opioid treatments for chronic pain. Its lead investigational programme is a proprietary low-dose naltrexone formulation for Complex Regional Pain Syndrome. The programme has received FDA orphan drug designation and is advancing through clinical development.
The company is also developing the Drew Clear Patch, a topical technology intended for targeted, non-invasive pain treatment. The biotech business is led by Dr. Amol Soin, whom AI Financial identifies as a pain management research and applications specialist. The company said Dr. Soin is the inventor of Biphasic release of Low-Dose Naltrexone and the Clear Patch topical application technology.
Isaac said the rebranding was the first in a series of pending announcements and that further initiatives would be introduced in the weeks ahead in connection with the company’s strategic plans for stockholders.
AI Financial’s forward-looking statements are subject to risks involving changes in the market price and trading volume of its common stock, volatility affecting WLFI tokens and other digital assets, and limits on the transfer, pledging, staking, lending or other use of its WLFI holdings. The company also cited the availability and terms of financing or liquidity arrangements, digital-asset custody, collateralisation, staking, lending, counterparty and protocol risks, access to capital, technology development or integration, execution under a new corporate identity and ticker symbol, market conditions and regulatory developments.
AI Financial said actual results could differ materially from forward-looking statements and referred to additional risks in its Securities and Exchange Commission filings.
AI Financial Corporation announced that Alyea Therapeutics Corporation will be rebranded as Drew Therapeutics Corporation.
The name honours Andrew Witkoff, who died from an opioid overdose in 2011 at the age of 22.
Drew Therapeutics is developing non-opioid pain treatments, including a low-dose naltrexone programme for Complex Regional Pain Syndrome and the Drew Clear Patch.
The biotech segment is intended to become a separate, independent public company, as previously announced.
AI Financial said additional initiatives are expected to be announced in the weeks ahead, subject to the risks outlined in its forward-looking statements.
AI Financial Corporation announced that its biotech segment will be rebranded as Drew Therapeutics Corporation. The new name honours Andrew Witkoff, the brother of Chairman Zach Witkoff, who died of an opioid overdose in 2011 at the age of 22.
AI Financial Corporation said the name honours Andrew Witkoff and aligns with the segment’s research into non-addictive treatments for pain. CEO Tony Isaac said Andrew’s story reinforces the company’s commitment to developing non-addictive painkillers, reducing pain and saving lives.
AI Financial Corporation’s biotech segment is currently developed and marketed under the legacy brand Alyea Therapeutics Corporation. The company said Alyea Therapeutics Corporation will be rebranded as Drew Therapeutics Corporation.
The biotech business focuses on developing innovative, non-opioid solutions for chronic pain. Its activities include the development of low-dose naltrexone and the Drew Clear Patch topical pain-relief technology.
Drew Therapeutics Corporation’s lead investigational programme is a proprietary formulation of low-dose naltrexone for Complex Regional Pain Syndrome, which has received FDA orphan drug designation and is advancing through clinical development. The company is also developing the Drew Clear Patch, a topical technology designed for targeted, non-invasive treatment.
The biotech business is headed by Dr Amol Soin, who the company describes as a leader in pain management research and applications. AI Financial Corporation said Dr Soin is the inventor of Biphasic release of Low-Dose Naltrexone and the Clear Patch topical application technology.
AI Financial Corporation said its biotech segment will become a separate, independent public company, as previously announced. Drew Therapeutics Corporation is currently described as a subsidiary of AI Financial Corporation that will become a separate, independent public company.
AI Financial Corporation said the new tagline is “From Pain Comes Purpose.” The company said it was inspired by responses to opioid-related tragedy that support awareness, outreach to families affected by addiction and investment in non-addicting pain treatments.
The announcement identifies AI Financial Corporation as trading on Nasdaq under AIFC and on the Frankfurt exchange under 5AR1. The company profile also lists the venues and symbols as NASDAQ:AIFC and FRA:5AR1.
CEO Tony Isaac said the rebranding is the first of a series of pending announcements. He said the company will roll out other initiatives in the weeks ahead to activate its strategic plans for the benefit of stockholders.
AI Financial Corporation identifies risks including changes in the market price and trading volume of its common stock, volatility in WLFI tokens and other digital assets, restrictions on its WLFI token holdings, financing and liquidity availability, digital-asset custody and counterparty risks, and access to capital for future development. It also cites risks related to developing, acquiring or integrating technologies, executing its strategy under its new corporate identity and ticker symbol, changing market conditions, regulatory developments and other risks described in its Securities and Exchange Commission filings.